Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6ed83b9d5c28c6c356d1d08d58501e7 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-215 |
filingDate |
2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6923154bd05764fd33e3326bffd216a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaca7d1a0b2550addc7c33bb54cd6f59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e059927336c584b203a16f5cd9a35134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4868e3f15bc0b0bad020e4308aa31659 |
publicationDate |
2020-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10639289-B2 |
titleOfInvention |
Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction |
abstract |
The present invention discloses an application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction, provides a correlation between neuraminidase and myocardial ischemic damage to prove the myocardial ischemic damage can be alleviated by inhibiting the activity of neuraminidase, and to prove the neuraminidase can be used as a target for screening drugs for preventing, alleviating and/or treating myocardial ischemic damage. The present invention also demonstrates the alleviating effect of neuraminidase inhibitors on myocardial ischemic damage. Neuraminidase inhibitors improves myocardial ischemic damage by reducing the level of neuraminidase. The present invention further provides a pharmaceutical preparation comprising neuraminidase inhibitor(s) and pharmaceutically acceptable carrier(s), the pharmaceutical preparation can be used for reducing the level of neuraminidase, thus improving myocardial ischemic damage. |
priorityDate |
2016-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |